<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940418-2-00133</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=83 g=1 f=1 -->  <!-- PJG 0012 frnewline --> A. Utility of the Series 42  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline --> The Amex, Phlx, NYSE, and CBOE argue that the usefulness of the Series 42 is limited because broker-dealers who trade options should understand the entire marketplace, especially instruments which underlie options. The Amex believes that the Series 42 will result in broker-dealers having only a narrow understanding of just one type of product, namely options. <FOOTCITE>18</FOOTCITE>  Furthermore, the Amex, CBOE, NYSE, and Phlx each believe that the Series 7 is the most effective way of ensuring that the investing pubic will be served by qualified and informed options representatives because the examination covers virtually every securities product trading on U.S. exchanges and the NASD Automated Quotation System (``NASDAQ''). <FOOTCITE>19</FOOTCITE>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> 18 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> See Amex Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  note 4.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FOOTNOTE>  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> 19 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> See Amex Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  note 4; CBOE June 24 Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  note 7; NYSE August 16 Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  note 5; and Phlx Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  note 6. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FOOTNOTE>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The Phlx, CBOE, and NYSE believe that except for the Series 62, <FOOTCITE>20</FOOTCITE>  the NASD's current limited product examinations can be justified because these examinations are intended to accommodate limited purpose broker-dealers and their representatives whose securities activities are limited to specific, discrete product lines, such as investment company products/variable annuities  <!-- PJG 0012 frnewline --> (Series 6), direct participation programs (Series 22), and  <!-- PJG 0012 frnewline --> municipal securities (Series 52) and, therefore, the potential  <!-- PJG 0012 frnewline --> for investor confusion is minimal. <FOOTCITE>21</FOOTCITE>  In this context, the CBOE  <!-- PJG 0012 frnewline --> notes that unlike the Series 42 and 62, the NASD's other limited  <!-- PJG 0012 frnewline --> product exams do not conflict with the current Series 7 test  <!-- PJG 0012 frnewline --> because such non-exchange traded securities are within the  <!-- PJG 0012 frnewline --> regulatory purview of the over-the-counter market. <FOOTCITE>22</FOOTCITE>  Further,  <!-- PJG 0012 frnewline --> the Phlx believes that the same economic efficiencies will not be  <!-- PJG 0012 frnewline --> realized from the implementation of the Series 42 because there  <!-- PJG 0012 frnewline --> is not a sufficient number of firms whose business is limited  <!-- PJG 0012 frnewline --> solely to options, or to corporate securities and options, to  <!-- PJG 0012 frnewline --> achieve these efficiencies. <FOOTCITE>23</FOOTCITE>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> 20 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> The Phlx, CBOE, and NYSE, believe that the introduction of  <!-- PJG 0012 frnewline --> the Series 62 added confusion to the existing regulatory  <!-- PJG 0012 frnewline --> scheme by creating multiple levels of qualification  <!-- PJG 0012 frnewline --> standards for stockbrokers.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> See <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  Phlx Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  note 6; CBOE June 24 Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 --> note 7; and NYSE August 16  <!-- PJG 0012 frnewline --> Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  note 5. The Commission notes, however, that  <!-- PJG 0012 frnewline --> it did not receive any written comments to the NASD proposal  <!-- PJG 0012 frnewline --> for the Series 62 exam prior to its approval. See Exchange Act Release No. 25719,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  note 13.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FOOTNOTE>  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> 21 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> Id. <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FOOTNOTE>  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> 22 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> See CBOE June 24 Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  note 7.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FOOTNOTE>  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> 23 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> See Phlx Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  note 6. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FOOTNOTE>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Finally, the CBOE and Phlx argue that the usefulness of the  <!-- PJG 0012 frnewline --> Series 42 is limited because it is likely that no national securities exchange will recognize the examination. <FOOTCITE>24</FOOTCITE>  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> 24 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> See CBOE June 24 Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  note 7; and Phlx Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 --> note 6.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FOOTNOTE>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> B. Investor Confusion  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline --> The CBOE and NYSE argue that the Series 42 will confuse investors by fragmenting the elements of qualification for the offering of listed securities options contracts, thus requiring an investor to determine whether or not his stockbroker is  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  qualified to accept his orders in certain products. <FOOTCITE>25</FOOTCITE>  The CBOE  <!-- PJG 0012 frnewline --> and NYSE also believe that the knowledge and capabilities of a  <!-- PJG 0012 frnewline --> limited product stockbroker may not be as sound as those of a  <!-- PJG 0012 frnewline --> stockbroker who is qualified for all products in the securities  <!-- PJG 0012 frnewline --> markets. For this reason, the CBOE and NYSE recommend that  <!-- PJG 0012 frnewline --> limited product representatives be required to disclose  <!-- PJG 0012 frnewline --> limited qualifications in writing. <FOOTCITE>26</FOOTCITE>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> 25 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> See CBOE June 24 Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  note 7; and NYSE August 16 Letter,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> supra  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 --> note 5.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FOOTNOTE>  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> 26 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> Id.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FOOTNOTE>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Further, the Phlx argues that use of the Series 42 could  <!-- PJG 0012 frnewline --> confuse and mislead public investors by creating specialized  <!-- PJG 0012 frnewline --> representatives within general purpose firms. <FOOTCITE>27</FOOTCITE>  The Phlx  <!-- PJG 0012 frnewline --> believes that it is possible that a representative qualified  <!-- PJG 0012 frnewline --> under the Series 42 and Series 62 examinations would be  <!-- PJG 0012 frnewline --> unqualified to make recommendations on the range of available  <!-- PJG 0012 frnewline --> investment products suitable to a particular customer, or might  <!-- PJG 0012 frnewline --> seek to dissuade an investor from pursuing certain otherwise  <!-- PJG 0012 frnewline --> appropriate investment products because the representative is not  <!-- PJG 0012 frnewline --> qualified to recommend them. <FOOTCITE>28</FOOTCITE>  Further, the Phlx believes that  <!-- PJG 0012 frnewline --> because there is no requirement for disclosing the capacities in  <!-- PJG 0012 frnewline --> which a representative is qualified, a customer would not know  <!-- PJG 0012 frnewline --> whether a representative was fully qualified, nor be able to  <!-- PJG 0012 frnewline --> assess any possible ``extraneous motives'' for a representative's  <!-- PJG 0012 frnewline --> advice. <FOOTCITE>29</FOOTCITE>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=3 --> 27 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=3 --> See Phlx Letter, supra  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 --> note 6. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FOOTNOTE>  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> 28 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> Id.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FOOTNOTE>  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=3 --> 29 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=3 --> Id.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FOOTNOTE>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            